Ann: Phase III Clinical Trial Investor Webinar, page-48

just another cbd oil not worth a crumpet as a regulatory approved cbd oil without any real market in unmet need ....
lol...yer rightio then.

https://au.investing.com/news/stock-market-news/fda-grants-orphan-drug-status-to-cardiols-heart-disease-drug-93CH-3119331

The FDA's ODD is aimed at encouraging the development of treatments for rare diseases—those affecting fewer than 200,000 people in the U.S. The designation comes with benefits such as potential seven-year marketing exclusivity, fee waivers, and tax credits for clinical trials. Moreover, drugs with ODD can potentially be fast-tracked for regulatory review.

up 48% overnight...wonder why?....lol
red or black - the numbers are correct